Literature DB >> 2447421

Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.

W R Kukovetz1, S Holzmann.   

Abstract

Nicorandil (SG-75) is a new organic nitrate with pronounced vasodilator properties. We studied whether nicorandil, in analogy to other nitrovasodilatators, exerted its relaxing effects on vascular smooth muscle by stimulating guanylate cyclase, and whether this effect was susceptible to tolerance development. Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators. It was found that nicorandil dose-dependently relaxed the strips precontracted with 26.7 mM K+ and that this effect was closely associated with increases in cGMP levels (measured by RIA under various conditions). The correlation between relaxation and rises in cGMP was steeper than with other nitrovasodilatators, suggesting that nicorandil, in addition to its cGMP-mediated effect, also relaxed vascular smooth muscle by a cGMP independent mechanism. In contrast to nitroglycerin (NG), nicorandil caused little development of tolerance or cross-tolerance toward ISDN or IS-5-MN when tested after preincubation of the strips toward the respective substance. Pretreatment with N-acetylcysteine during the preincubation period prevented tolerance towards nicorandil. The results indicate that the relaxant effects of nicorandil consist of a larger cGMP-mediated component and a smaller one which is independent of this nucleotide.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447421

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Contribution of cyclic GMP formation to KRN2391-induced relaxation in coronary artery of the pig.

Authors:  Y Jinno; H Kasai; H Ohta; K Nishikori; H Fukushima; N Ogawa
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

Review 2.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  In vitro protective effects of nicorandil on hypothermic injury to immature cardiac myocytes: comparison with nitroglycerin.

Authors:  H Orita; M Fukasawa; S Hirooka; K Fukui; M Kohi; M Washio
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

4.  Effects of nicorandil on cell proliferation and cholesteryl ester accumulation in arterial smooth muscle cells in culture.

Authors:  R Fujiwara; T Hayashi; Y Kutsumi; K Oida; T Tamai; T Nakai; S Miyabo
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

5.  Comparison of the development of tolerance to nitroglycerin in aortic preparations isolated from non-diabetic and diabetic rats.

Authors:  T Matsuzaki; M Sakanashi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

Review 6.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

7.  Mechanisms of nitrate-induced vasodilatation and tolerance.

Authors:  W R Kukovetz; S Holzmann
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.